Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @AntonyMarra
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AntonyMarra
-
Our latest review on pathogenesis and clinical management of breast implant-associated anaplastic large cell lymphoma just out on
#CTR
Regular follow-up in women with textured implants
Multidisciplinary approach is essential
@curijoey@GPravettoni@IEOufficiale@LaStatalehttps://twitter.com/curijoey/status/1219293539886039040 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
Featured article this month is the Perspective from
@DanChenMDPhD & Priti Hegde: "Top 10 Challenges in#Cancer#Immunotherapy" | Discusses the top 10 challenges facing this field & what is necessary to overcome them https://authors.elsevier.com/a/1aP1-3qNrUfz1S …pic.twitter.com/1fBSI1kiKD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
Kudos to
@EnedaToska for thinking, managing and pushing thru the finish line our new work now out in Nat Gen. She is more than ready to run her lab.@sloan_kettering@DanaFarber@baselga1@CKadoch and more.#breastcancer Here is the link and a tweetorialhttps://go.nature.com/2QOTkX9Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
Study presents an interactive CAR clinical trial database, spanning 64 targets in T cells, NK cells or mixtures of both, which suggests a landscape of >100 single targets and >100,000 possible target pairs using logical switches for CAR cell engineering:https://www.nature.com/articles/s41587-019-0329-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NRRJ_2_SJB_nrclinonc_editorial_socialposts …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
A guide for young residents!
@myESMO @OncoAlert @LaStatalepic.twitter.com/KgPXJSWLWo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
Is there an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Our work out for Christmas! https://www.mdpi.com/2072-6694/12/1/67 …
@franligorio@emmazattarin@AntonyMarra@RobertoFerrara_@marinagarassino@MDPIOpenAccess@Cancers_MDPIPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
BRCA1 mut, PD-L1 negative TNBC patient with liver mets, ECOG 0. Given the chance of internal 2nd line PARPi clinical trial, what’s your 1st line Tx choice?
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
Top presentations
@SABCSSanAntonio: HER2Climb - tucatinib DESTINYbreast01 - DS8201 APHINITY- perjeta OS update ATEMPT - adjuvant TDM1 Two on adj capecitabine PEARL palbo/ET vs chemo Keynote522 / neoTRIPaPDL1 neoadj PD1/PDL1 in TNBC MRI vs mammo in FH pts RCB data oral taxaneHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
"We almost fell off our chairs." According to a new MSK study in
@NatureMedicine by@PedramRazavi, Bob Li, and Jorge Reis-Filho, many mutations found in#liquidbiopsies don’t come from tumor cells but from alterations in white blood cells.@MSKPathologyhttp://bit.ly/2KTyBOCHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PDL1 amplification can be detected in 0.7% of all solid tumors and is able to predict durable responses to anti-PD-1/PD-L1
#immunotherapy even in absence of microsatellite instability, high PD-L1 expression and a high TMBhttps://jamanetwork.com/journals/jamaoncology/fullarticle/2684636 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nice and interesting work on the role of PTEN loss in cross-resistance to CDK4/6 and PI3Kα inhibitors in
#breastcancer, suggesting potential and considerable implications for optimal treatment sequencing strategies in mBC#bcsm @OncoAlerthttps://cancerdiscovery.aacrjournals.org/content/early/2019/10/08/2159-8290.CD-18-0830 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
With all the residents after exciting examinations, they are about to start 4th year (except Giovanni Fuca’ just back from UNC)
@curijoey young docs empowermentpic.twitter.com/AL4ChhkWFE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Interesting work just presented at
#ESMO19 and simultaneously published in@Annals_Oncology - sTILs can identify a subgroup of stage I#TNBC pts with excellent prognosis without adjuvant CT@curijoey@FAndreMD @LoiSher@vitti10 @OncoAlerthttps://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdz395/5575078?redirectedFrom=fulltext …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
The
@IEOufficiale and UNIMI team ready for the@myESMO YOC party: a must-to after a full day of meetings and sessions started at 6 AM and finished...3 AM still ongoing!!! Who will pay Coffey for All, tomorrow?pic.twitter.com/h85bkJNmPP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
MONARCH-2 trial demonstrated statistically significant improvement in OS with the addiction of abemaciclib to fulvestrant in metastatic HR+ HER2- breast cancer
#bcsm#ESMO19@OncoAlertpic.twitter.com/xhhu1HECWF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New and proper biomarkers are definitely needed to better select TNBC patients for next-generation immunotherapy trials. Great and inspiring talk by
@curijoey on new frontiers in#TNBC treatment#bcsm#ESMO19@OncoAlertpic.twitter.com/x5ETul8PYG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
monarchHER trial met its primary endpoint (PFS), suggesting a role for abemaciclib in combination with fulvestrant and trastuzumab in metastatic triple-positive breast cancer
#bcsm#ESMO19@OncoAlertpic.twitter.com/SdYjvsy2bg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
ESMO Lifetime Achievement Award - Angelo Di Leo: for his outstanding career dedicated to
#cancer research & education. An internationally renowned expert in#breastcancer who pioneered research & contributed signif 2 dev of personalised treatmt approaches http://bit.ly/2lzLCTu pic.twitter.com/9vR8qMl4nu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Are all CDK4/6 inhibitors created equal? | Just published on
@Nature_NPJ#BreastCancer our article on clinical and pharmacological differences of CDK4/6 inhibitors in breast cancer treatment @curijoey @OncoAlert#bcsmhttps://www.nature.com/articles/s41523-019-0121-y …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Antonio Marra proslijedio/la je Tweet
Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdz235/5543097#.XUU-v-O-hA4.twitter …
@OncoAlertHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.